Modality
Degrader
MOA
TROP-2 ADC
Target
Aβ
Pathway
T-cell
HSPBCCRC
Development Pipeline
Preclinical
~Feb 2014
→ ~May 2015
Phase 1
~Aug 2015
→ ~Nov 2016
Phase 2
Feb 2017
→ Jan 2029
Phase 2Current
NCT06245982
2,342 pts·PBC
2017-02→2029-01·Not yet recruiting
2,342 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-01-032.8y awayPh3 Readout· PBC
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P2/3
Not yet…
Catalysts
Ph3 Readout
2029-01-03 · 2.8y away
PBC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06245982 | Phase 2/3 | PBC | Not yet recr... | 2342 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| ARG-314 | Argenx | Approved | Aβ | |
| GMA-5010 | Genmab | Phase 3 | JAK2 |